THE 60-SECOND GUIDE
Melanotan II
Unapproved peptide · limited controlled evidence.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
Melanotan II is a synthetic melanocortin analog investigated for pigmentation and sexual effects. It is distinct from bremelanotide, the ingredient in approved Vyleesi. Activity at related receptors does not transfer another medicine’s approval, clinical evidence, or safety profile to Melanotan II. [1]
Potential benefits
Activates melanocortin pathways associated with pigmentation and sexual effects. Helped inform later melanocortin drug development. [1]
Evidence & its limits
The early trial was far too small to establish broad safety. FDA lists serious published adverse-event reports associated with Melanotan II, including priapism and neurological complications; case reports signal concern but do not establish how frequently an event occurs or prove causation. [1]
Risks & unknowns
Not FDA-approved. Associated with nausea, pigment changes, priapism, and uncertain product quality. [1]
Status & scope
It is distinct from bremelanotide, the ingredient in approved Vyleesi. Activity at related receptors does not transfer another medicine’s approval, clinical evidence, or safety profile to Melanotan II. Not FDA-approved. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- Melanotan-II pilot phase I study, 1996
- FDA Drugs@FDA database
- FDA Melanotan II safety concerns
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.